News & events

Stereotaxis Completes Acquisition of Robocath

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has completed its previously announced acquisition of Robocath, an innovator of robotic technologies for interventional cardiology and neurointerventions.

Robocath will now be fully integrated into Stereotaxis, combining complementary technologies and expertise to accelerate the development of next-generation robotic solutions for electrophysiology, interventional cardiology, and neurointerventions. The combined platform strengthens Stereotaxis’s position as the leader…

Robocath completes enrollment in First-In-Human (FIH) study of next-gen robotic platform in interventional cardiology.

Press release: 260511 Robocath world first completed

We are particularly proud to share that Robocath is becoming part of Stereotaxis, a major step that brings together two global leaders with a shared ambition : to shape the future of endovascular care.

Beyond the strategic rationale, this moment is first and foremost about people, vision, and leadership. Joining Stereotaxis under David Fischel’s leadership is both inspiring and reassuring. His vision, combined with the strength of the teams, creates a powerful foundation to…

In 2025, 5 Shanghai hospitals chose R-One, sold, installed and serviced by our JV Cathbot.

From Europe to China: Building a Global Vision for Robotic-Assisted Interventional Cardiology

Robocath is pleased to announce the installation of its R-One+ robotic system at Kwong Wah Hospital in Hong Kong, implemented through its joint venture Cathbot.

This important milestone reflects our commitment to advancing robot-assisted interventional cardiology and expanding access to innovative, minimally invasive solutions across Asia. The R-One+ system is designed to enhance procedural precision, safety, and efficiency, supporting physicians in delivering high-quality cardiovascular care.

We are proud to collaborate with Kwong Wah Hospital and Cathbot to help…

We are pleased to share a recent milestone achieved by Rheinland Klinikum Neuss GmbH. Their cardiology team at Lukaskrankenhaus has successfully enrolled the 100th patient in the Robocath CHANGE Registry, marking an important step in the evaluation of robotic-assisted coronary interventions:

Our cardiology experts at Lukaskrankenhaus have successfully enrolled the 100th patient in the Robocath CHANGE Registry — congratulations to the entire team on reaching this important milestone.

CHANGE is a real-world registry…

Rouen, France, January 27, 2026 – Robocath, a global leader in robotic solutions dedicated to interventional cardiology, today announces the launch of the world’s first FIH (First-In-Human) clinical study evaluating its new robotic system in coronary artery disease.

This second-generation robot, developed thanks to the clinical and technological experience Robocath gained with its first robotic platform – which is already deployed in numerous centers worldwide – integrates unprecedented and unrivaled capabilities designed to meet the increasing demands of complex coronary…

University Martin Hospital (Slovakia) has installed the R-One+ robotic system to advance research in interventional neuroradiology.

The programme is led by Professor Kamil Zeleňák, Head of Interventional Neuroradiology, Chair of the ESMINT AI & Robotics Ad hoc Committee and Congress President 2025, a recognised pioneer in robotic-assisted interventions.

This collaboration supports advanced research in procedural accuracy, reproducibility, radioprotection, and data-driven innovation, reinforcing Robocath’s commitment to shaping…

We’re proud to share the publication of the CARE study in the Interventional Neuroradiology Journal:
🧠 “Robotic-assisted carotid artery stenting with R-One™: Feasibility and safety assessment in patients with carotid web lesions”
📖 Now available in open access → Read the full article

This prospective study demonstrates the feasibility and procedural safety of using the R-One™ robotic platform to perform carotid artery stenting (CAS).

💡 With an 86% technical success rate and no intraprocedural complications, these results…

Rouen, France, May 15, 2024 – Robocath, a company that designs, develops and markets innovative robotic solutions to treat cardiovascular and neurovascular diseases, today announces the publication of a new report into current and future expectations for the use of robotics in interventional medicine.

The report sets out the findings from an independent study conducted by Suazio Consulting. It involved 30 interventional cardiologists based in the US, Europe and Asia.

The study reveals growing support for the use of robotics…